Close Menu

Becton Dickinson

The firm is projecting COVID-19 testing revenues of $865 million in the recently completed quarter, including $685 million in Veritor immunoassay sales.

Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.

News items for the week of Nov. 23, 2020.

For the full year, the Franklin Lakes, New Jersey company saw a decline in revenues of 1 percent compared to 2019.

The firms previously received CE mark for a COVID-19 test on the BD Max system in March.

Nevada's About Face

The New York Times reports Nevada has reversed a statewide order directing nursing homes to halt their use of two rapid coronavirus tests.

The RT-PCR-based test, which runs on Becton Dickinson's BD Max system, simultaneously detects SARS-CoV-2, influenza A and B, and respiratory syncytial virus.

The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.

According to the Wall Street Journal, Becton Dickinson is investigating reports from nursing homes regarding false positive results from its rapid COVID-19 test.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.